Intelligence Platform
Surface licensing opportunities from Chinese regulatory filings, clinical trials, and financial data — months before traditional channels.
25
Companies
200+
Molecules
6
Data Sources
6h
Sync Cadence
Platform
01
Scored feed of Chinese oncology molecules ranked by BD relevance. Filter by phase, modality, target, and therapeutic area.
02
Auto-generated profiles with financials, pipeline depth, regulatory history, and deal track record.
03
Real-time notifications for new filings, approvals, trial milestones, and deal announcements.
Sources
SEC EDGAR
20-F, 10-K annual reports and 6-K current reports for US-listed Chinese biotechs.
HKEX
Annual and interim reports from HK-listed biopharma companies under Chapter 18A.
NMPA / CDE
IND/NDA filings, approval decisions, and clinical trial registrations from China's drug authority.
ChiCTR
China-registered clinical trials with enrollment data, endpoints, and site locations.
ClinicalTrials.gov
Global trial registrations cross-referenced with Chinese sponsor companies.
CNIPA
Patent filings and IP landscape for tracked molecules and therapeutic targets.
KirinBD surfaces licensing signals from Chinese biopharma data before they hit the conference circuit.